Cardiol Therapeutics (CRDL) News Today → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free CRDL Stock Alerts $1.81 +0.01 (+0.56%) (As of 03/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLeede Jones Gab Analysts Raise Earnings Estimates for Cardiol Therapeutics Inc. (NASDAQ:CRDL)americanbankingnews.com - March 29 at 1:54 AMCardiol Therapeutics Inc. (NASDAQ:CRDL) Forecasted to Post FY2024 Earnings of ($0.31) Per Sharemarketbeat.com - March 28 at 8:44 AMCardiol Therapeutics (CRDL) to Release Earnings on Tuesdaymarketbeat.com - March 25 at 7:31 AMCardiol Therapeutics (NASDAQ:CRDL) and Moderna (NASDAQ:MRNA) Head to Head Comparisonamericanbankingnews.com - March 25 at 1:18 AMClosing Bell: Cardiol Therapeutics Inc Purchase WT down on Friday (CRDL-WT-A)theglobeandmail.com - March 16 at 8:07 AMShort Interest in Cardiol Therapeutics Inc. (NASDAQ:CRDL) Increases By 108.1%marketbeat.com - March 13 at 3:59 PMCardiol Therapeutics Stock (NASDAQ:CRDL), Short Interest Reportbenzinga.com - February 22 at 5:11 PMCardiol Therapeutics wraps up patient enrollment for Phase II open label studyproactiveinvestors.com - February 21 at 9:55 AMCardiol CEO David Elsley unpacks FDA Orphan Drug Designation for Cardiolproactiveinvestors.com - February 16 at 3:07 PMCardiol Therapeutics receives orphan drug status for its lead drug...proactiveinvestors.com - February 15 at 1:48 PMOrphan Drug Designation Sends Shares of this Dual-Listed Life Science Therapy Company Soaringtheglobeandmail.com - February 15 at 1:48 PMCardiol stock rallies 28% on FDA orphan drug status for CardiolRxmsn.com - February 15 at 1:48 PMCardiol Therapeutics receives orphan drug status for its lead drug candidateproactiveinvestors.com - February 15 at 9:49 AMShort Interest in Cardiol Therapeutics Inc. (NASDAQ:CRDL) Drops By 9.0%marketbeat.com - January 30 at 8:23 AMCardiol Therapeutics Inc Class A CRDLmorningstar.com - January 9 at 11:47 PMCardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditisfinance.yahoo.com - January 9 at 8:46 AMClosing Bell: Cardiol Therapeutics Inc Purchase WT down on Tuesday (CRDL-WT-A)theglobeandmail.com - December 18 at 7:09 AMCardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseasesfinance.yahoo.com - November 16 at 8:15 AMCardiol Therapeutics releases positive study results of subcutaneously administered cannabidiolfinance.yahoo.com - October 11 at 1:19 PMCardiol Therapeutics says study results show positive effects of subcutaneously administered cannabidiolproactiveinvestors.com - October 10 at 10:23 AMCardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fractionfinance.yahoo.com - October 10 at 10:23 AMCardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)benzinga.com - October 2 at 10:02 AMHere's Why You May Invest in Cardiol Therapeutics (CRDL) Stockfinance.yahoo.com - September 27 at 12:36 PMCardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditisfinance.yahoo.com - September 19 at 9:24 AMIs Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - August 26 at 4:55 PMCardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conferencefinance.yahoo.com - August 9 at 8:00 AMClosing Bell: Cardiol Therapeutics Inc flat on Wednesday (CRDL)theglobeandmail.com - August 4 at 11:07 PMCardiol Therapeutics Reports Results of 2023 Annual General Meetingfinance.yahoo.com - June 29 at 2:01 PMCardiol Therapeutics earns higher price target from broker as it ends 1Q with sufficient cash to advance CardiolRx candidateproactiveinvestors.com - May 23 at 4:29 PMClosing Bell: Cardiol Therapeutics Inc down on Thursday (CRDL)theglobeandmail.com - April 28 at 3:49 AMClosing Bell: Cardiol Therapeutics Inc up on Wednesday (CRDL)theglobeandmail.com - April 19 at 10:44 PMClosing Bell: Cardiol Therapeutics Inc down on Tuesday (CRDL)theglobeandmail.com - April 19 at 7:43 AMClosing Bell: Cardiol Therapeutics Inc down on Friday (CRDL)theglobeandmail.com - April 14 at 9:02 PMClosing Bell: Cardiol Therapeutics Inc up on Monday (CRDL)theglobeandmail.com - April 11 at 8:05 AMCardiol Therapeutics offers an update on operations as it advances the development of its lead drug candidate CardiolRxproactiveinvestors.com - March 29 at 10:41 PMCardiol Therapeutics Announces Year-End 2022 Update on Operationsfinance.yahoo.com - March 29 at 7:39 AMCardiol Therapeutics says new study results highlight the cardioprotective effects of cannabidiolproactiveinvestors.com - March 7 at 5:06 PMCardiol Therapeutics says first patient enrolled in Phase 2 study of CardiolRx for Pericarditisfinance.yahoo.com - January 17 at 4:21 PMCardiol Therapeutics enrolls first patient in Phase II CardiolRx study on recurrent pericarditisproactiveinvestors.com - January 17 at 10:21 AMCardiol Therapeutics commences Phase II study of CardiolRx for treatment of Recurrent Pericarditisproactiveinvestors.com - December 14 at 1:49 PMCardiol Therapeutics kicks off a multi-center Phase II pilot study of CardiolRx for the treatment of recurrent pericarditisproactiveinvestors.com - December 12 at 4:20 PMCardiol Therapeutics unveils new study data highlighting protective effects of CardiolRx in acute pericarditisproactiveinvestors.com - November 7 at 11:06 AMCardiol to abandon COVID study of cannabis drug to focus on heart diseases trialsseekingalpha.com - October 25 at 8:38 AMCardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditisfinance.yahoo.com - August 3 at 7:57 AMCardiol Therapeutics Inc. (TSE:CRDL): Are Analysts Optimistic?finance.yahoo.com - July 12 at 7:01 AMCardiol Therapeutics Announces At-The-Market Equity Offering Programfinance.yahoo.com - June 9 at 4:18 PMCardiol Therapeutics (NASDAQ:CRDL), Earnings Estimates, EPS, and Revenuebenzinga.com - June 1 at 4:24 PMCardiol Therapeutics appoints Teri Loxam and CFO Chris Waddick to its board of directorsproactiveinvestors.com.au - May 19 at 9:51 AMCardiol Therapeutics receives US FDA authorization for Phase II study of CardiolRx for recurrent pericarditisproactiveinvestors.com.au - May 17 at 4:55 PMCardiol Therapeutics gets FDA go ahead for Investigational New Drug Application for CardiolRxproactiveinvestors.com - May 17 at 4:55 PM Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address Central Banks Preparing for US Dollar Collapse? (Ad)China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies. Find out how you can protect yourself now >>> CRDL Media Mentions By Week CRDL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRDL News Sentiment▼0.980.61▲Average Medical News Sentiment CRDL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRDL Articles This Week▼70▲CRDL Articles Average Week Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LIFE News BLUE News SGMO News OTLK News CLLS News MOLN News BCAB News CVM News VIGL News ATHA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRDL) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.